Blood-Based Next-Generation Sequencing Analysis of Appendiceal Cancers.
Walid L ShaibKaterina ZakkaCharles StaleyAli RobertsMehmet AkceChristina WuOlatunji B AleseBassel F El-RayesPublished in: The oncologist (2019)
The complexity of appendiceal cancer and its unique genomic characteristics suggest that customized combination therapy may be required for many patients. Theoretically, as more oncogenic pathways are discovered and more targeted therapies are approved, customized treatment based on the patient's unique molecular profile will lead to personalized care and improve patient outcomes. Liquid biopsies are noninvasive, cost-effective, and promising methods that provide patients with access to personalized treatment.
Keyphrases
- combination therapy
- end stage renal disease
- healthcare
- low grade
- chronic kidney disease
- newly diagnosed
- ejection fraction
- copy number
- palliative care
- squamous cell carcinoma
- prognostic factors
- papillary thyroid
- quality improvement
- single molecule
- patient reported outcomes
- young adults
- genome wide
- chronic pain
- health insurance
- drug administration